Cargando…

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy

BACKGROUND: The correlation between blood-based tumor mutation burden (bTMB) and tissue-based tumor mutation burden(tTMB) has not been broadly tested in a multicancer cohort. Here, we assess the correlation between bTMB with tTMB in phase I trial patients treated with immunotherapy. As an explorator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araujo, Daniel V, Wang, Ao, Torti, Dax, Leon, Alberto, Marsh, Kayla, McCarthy, Aoife, Berman, Hal, Spreafico, Anna, Hansen, Aaron R, Razak, Albiruni-Abdul, Bedard, Philippe L, Wang, Lisa, Plackmann, Eric, Chow, Helen, Bao, Hua, Wu, Xue, Pugh, Trevor J, Siu, Lillian L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152803/ https://www.ncbi.nlm.nih.gov/pubmed/34056539 http://dx.doi.org/10.1093/jncics/pkaa122

Ejemplares similares

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
por: Cindy Yang, S. Y., et al.
Publicado: (2021)

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020)

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
por: Janse van Rensburg, Helena J., et al.
Publicado: (2023)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
por: Day, Daphne, et al.
Publicado: (2019)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
por: Stockley, Tracy L., et al.
Publicado: (2016)

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
por: Richter, Suzanne, et al.
Publicado: (2013)

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
por: Ala‐Leppilampi, Kari, et al.
Publicado: (2020)

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
por: Leung, Eric, et al.
Publicado: (2021)

Benign Smooth Muscle Tumors (Leiomyomas) of Deep Somatic Soft Tissue
por: McCarthy, Aoife J., et al.
Publicado: (2018)

Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor
por: Quevedo, Rene, et al.
Publicado: (2020)

Designing circulating tumor DNA-based interventional clinical trials in oncology
por: Araujo, Daniel V., et al.
Publicado: (2019)

Increasing operational and scientific efficiency in clinical trials
por: Kelly, Deirdre, et al.
Publicado: (2020)

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
por: Voon, Pei Jye, et al.
Publicado: (2022)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
por: Weberpals, Johanne I., et al.
Publicado: (2021)

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
por: Genta, Sofia, et al.
Publicado: (2023)

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
por: Chiu, Joanne W., et al.
Publicado: (2015)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
por: Cunningham, Morven, et al.
Publicado: (2021)

Desmoid Tumors in Familial Adenomatous Polyposis Patients: Favorable Outcomes with Multidisciplinary Management
por: Al-Sukhni, Eisar, et al.
Publicado: (2023)

Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial
por: Hernando‐Calvo, Alberto, et al.
Publicado: (2023)

Finding the way to Wilms tumor by comparing the primary and relapse tumor samples
por: Spreafico, Filippo, et al.
Publicado: (2022)

Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
por: Wong, Derek, et al.
Publicado: (2023)

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
por: Clouthier, Derek L., et al.
Publicado: (2019)

Spatial Organization and Correlations of Cell Nuclei in Brain Tumors
por: Jiao, Yang, et al.
Publicado: (2011)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: Oliva, Marc, et al.
Publicado: (2021)

Additional germline findings from a tumor profiling program
por: Stjepanovic, Neda, et al.
Publicado: (2018)

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
por: de Jonge, Maja J. A., et al.
Publicado: (2019)

Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review
por: McCarthy, Aoife J., et al.
Publicado: (2019)

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges
por: Sanz-Garcia, Enrique, et al.
Publicado: (2022)

ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer
por: Gupta, Nikhil, et al.
Publicado: (2019)

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer
por: Aung, Kyaw L., et al.
Publicado: (2016)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_q2sgrcrq3c452u0vbkmnb2e673